Effect of RO318220 on calpeptin-pretreated platelets
RO318220, μM . | Calpeptin, 100 μM . | % platelets positive . | Relative fluorescence . | % positive outside platelets . |
|---|---|---|---|---|
| 0 | No | 2.4 | 4000 | 1.7 |
| 0 | Yes | 4.9 | 8000 | 1.8 |
| 100 | No | 97.0 | 280 | 1.3 |
| 100 | Yes | 93.0 | 200 | 0.13 |
RO318220, μM . | Calpeptin, 100 μM . | % platelets positive . | Relative fluorescence . | % positive outside platelets . |
|---|---|---|---|---|
| 0 | No | 2.4 | 4000 | 1.7 |
| 0 | Yes | 4.9 | 8000 | 1.8 |
| 100 | No | 97.0 | 280 | 1.3 |
| 100 | Yes | 93.0 | 200 | 0.13 |
Gel-filtered, aspirin-treated platelets pretreated 10 minutes with 100 μM calpeptin prior to being treated with DMSO or RO318220 were activated with thrombin (0.2 U/mL) in the presence of FITC-labeled annexin V. The platelet population was defined by positive FITC-anti-GP1b fluorescence. Compensation was set to minimize RO318220 fluorescence spillover into either FL-2 or FL-1. The negative gates were set with an EDTA control. Positive events were analyzed within and outside the platelet population. Results were averaged from 3 experiments.